A decade ago, when TAVR was first cleared by the FDA, surgeons had concern about losing business. But unexpectedly, TAVR has helped also gain heart surgery cases. 

An international team of researchers, led by specialists from Cleveland Clinic, found that DAPT was consistently linked to a greater risk of major or life-threatening bleeding events. 

Philippe Genereux, MD, medical director of the structural heart disease program at Morristown Medical Center, discusses the various options used for temporary pacing of the heart during transcatheter aortic valve replacement (TAVR) procedures.

Researchers from Cleveland Clinic reviewed data from more than 400 patients, presenting their findings in the American Journal of Cardiology.

Not all hospitals respect the written preferences of patients, possibly motivated by a desire to report better TAVR outcomes.

Treating subclinical leaflet thrombosis after TAVR has been an ongoing challenge for structural heart clinicians, but recent research has gone a long way toward improving our understanding of this important topic.